ReviewCancer treatment reviews2021
Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000-19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4.
Review in Cancer treatment reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 69 citations in OpenAlex.
- Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions.MedComm · 2026Review
- Machine learning-assisted identification and validation of NRP1 inhibitors through molecular docking and dynamics simulations.Scientific reports · 2026Article
- Premature mortality projection for cardiovascular diseases to 2030: a sub-national evaluation towards the SDG 3.4 goals in China.The Lancet regional health. Western Pacific · 2026Article
- Cardiovascular disease risk perception and stages of preventive behaviours: a community survey in Pokhara Metropolitan, Nepal.BMJ open · 2026Article
- Association between cancer and cardiovascular disease risk: a cross-sectional study of 241,064 individuals.Frontiers in oncology · 2026Article
- Article
- Article
- Global Trends and Forecast of Cardiovascular Diseases, Cancer, and Shared Risk Factors: Insights From the GBD 2021.Journal of the American Heart Association · 2025Article
- Forecasting global progress in breast cancer control in the context of the sustainable development goals.BMJ global health · 2025Article
- Advance at a glance: contributions to cardio-oncology.European heart journal open · 2025Article
- Natural products and cancer: The urgent need to bridge the gap between preclinical and clinical research.World journal of gastrointestinal oncology · 2025Article
- Current Concepts in the Management and Treatment of Spinal Metastases-A Systematic Literature Review.Cancers · 2025Review
- Generalized structural equation modeling of direct and indirect determinants of chronic undernutrition among under-five children in Ethiopia: further analysis of the 2019 mini Ethiopian demographic and health survey.Journal of health, population, and nutrition · 2025Article
- Article
- Unveiling the Complexities: Exploring Mechanisms of Anthracyclineinduced Cardiotoxicity.Current cardiology reviews · 2025Review
- Variants in the neuropeptide geneAmerican journal of cancer research · 2025Article
- Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.Life (Basel, Switzerland) · 2024Review
- Transition towards cancer mortality predominance over cardiovascular disease mortality in Brazil, 2000-2019: a population-based study.Lancet regional health. Americas · 2024Article
- Evaluation of the cytotoxic activity of chemically characterized propolis originating from different geographic regions and vitamin D co-supplementation against human ovarian cancer cells.Journal of ovarian research · 2024Article
- Evaluation of the Therapeutic Potential of Amantadine in a Vincristine-Induced Peripheral Neuropathy Model in Rats.Animals : an open access journal from MDPI · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
With the 2030 Sustainable Development Goals (SDG) target of a one-third reduction in noncommunicable diseases (NCDs) less than a decade away, it is timely to assess national progress in reducing premature deaths from the two leading causes of mortality worldwide. We examine trends in the probability of dying ages 30-70 from cardiovascular disease (CVD) and cancer 2000-19 in 10 middle-income (MICs) and 10 high-income (HICs) countries with high quality data. We then predict whether the SDG target will be met in each country for CVD, cancer and for the four main NCDs combined. Downward trends were more evident in HICs relative to the MICs, and for CVD relative to cancer. CVD and cancer declines ranged from 30-60% and 20-30% in HICs over the 20-year period, but progress was less uniform among the MICs. Premature deaths from cancer exceeded CVD in nine of the 10 HICs by 2000 and in all 10 by 2019; in contrast, CVD mortality exceeded cancer in all 10 MICs in 2000 and remained the leading cause in eight countries by 2019. Two of the 10 MICs (Colombia and Kazakhstan) and seven of the HICs (Australia, Chile, Italy, New Zealand, Norway, Slovakia, and the U.K.) are predicted to meet the SDG NCDs target. Whether countries are on course to meet the target by 2030 reflects changing risk factor profiles and the extent to which effective preventative and medical care interventions have been implemented. In addition, lessons can be learned given people living with NCDs are more susceptible to severe COVID-19 illness and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.